Molecular Mechanisms Underlying Recurrence in Triple-Positive Breast Cancer (ER+/PR+/HER2+) and Potential Repurposing of Multi-Target Inhibitors
International Journal of Molecular Sciences · 16.06.2026 · 27 (12) · 5440
DOI: 10.3390/ijms27125440 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.06.2026. Verfasst von Cindy Bandala und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Medicina Traslacional, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, …. Hauptthemen laut MEDLINE: Drug Repositioning, Neoplasm Recurrence, Local, Breast Neoplasms, Antineoplastic Agents. Die Arbeit nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto Politécnico Nacional.
Abstract (Originalsprache)
Triple-positive breast cancer (TPBC) is characterized by the overexpression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), making its management a therapeutic challenge. Despite the availability of targeted therapies, patients with TPBC often experience recurrence and poor clinical outcomes due to intrinsic and acquired resistance mechanisms. This review summarizes current therapeutic approaches and their limitations, highlights the molecular mechanisms underlying treatment resistance and recurrence, and explores opportunities for drug repurposing, particularly involving multi-target inhibitors. Special emphasis is placed on the interaction between hormone receptor and growth factor receptor pathways, compensatory signaling mechanisms, and predictive biomarkers of recurrence. Furthermore, emerging strategies for drug repurposing using clinically available drugs are analyzed, including in silico, in vitro, and clinical trial evidence, along with their translational implications. Finally, we conclude that drug repurposing and multi-target approaches offer a compelling rationale for the development of novel therapeutic strategies in triple-positive breast cancer. However, their clinical utility remains to be validated through appropriately designed experimental and clinical studies before their impact on recurrence outcomes can be established.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratorio de Medicina Traslacional, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Salvador Diaz Mirón s/n, Casco de Santo Tomás, Migu…
- Laboratorio de Diseño y Desarrollo de Nuevos Fármacos e Innovación Biotecnológica, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Salvad…
ORCID-Profile: Cindy Bandala, José Anselmo López-Méndez, Jazmín Carro-Rodríguez, Martiniano Bello
Förderung
- Instituto Politécnico Nacional
Zitieren
APA
Bandala, C., López-Méndez, J. A., Díaz-Rivera, M. R. J., Carro-Rodríguez, J., & Bello, M. (2026). Molecular Mechanisms Underlying Recurrence in Triple-Positive Breast Cancer (ER+/PR+/HER2+) and Potential Repurposing of Multi-Target Inhibitors. International Journal of Molecular Sciences, 27(12), 5440. https://doi.org/10.3390/ijms27125440
Vancouver
Bandala C, López-Méndez JA, Díaz-Rivera MRJ, Carro-Rodríguez J, Bello M. Molecular Mechanisms Underlying Recurrence in Triple-Positive Breast Cancer (ER+/PR+/HER2+) and Potential Repurposing of Multi-Target Inhibitors. International Journal of Molecular Sciences. 2026;27(12):5440. doi:10.3390/ijms27125440
BibTeX
@article{Bandala2026,
author = {Bandala, Cindy and López-Méndez, José Anselmo and Díaz-Rivera, María R J and Carro-Rodríguez, Jazmín and Bello, Martiniano},
title = {Molecular Mechanisms Underlying Recurrence in Triple-Positive Breast Cancer (ER+/PR+/HER2+) and Potential Repurposing of Multi-Target Inhibitors},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {12},
pages = {5440},
doi = {10.3390/ijms27125440}
}
EUVIMED